



## Lynparza

### Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155.** If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to [do\\_not\\_call@cvscaremark.com](mailto:do_not_call@cvscaremark.com). An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: \_\_\_\_\_ Date: \_\_\_\_\_  
Patient's ID: \_\_\_\_\_ Patient's Date of Birth: \_\_\_\_\_  
Physician's Name: \_\_\_\_\_ NPI#: \_\_\_\_\_  
Specialty: \_\_\_\_\_  
Physician Office Telephone: \_\_\_\_\_ Physician Office Fax: \_\_\_\_\_  
Request Initiated For: \_\_\_\_\_

1. What is the diagnosis/indication?  
☐ Epithelial ovarian, fallopian tube, or primary peritoneal cancer ☐ Breast cancer  
☐ Pancreatic adenocarcinoma (pancreatic cancer) ☐ Prostate cancer  
☐ Uterine leiomyosarcoma  
☐ Other \_\_\_\_\_
2. What is the ICD-10 code? \_\_\_\_\_
3. What clinical setting will the requested drug be used in?  
☐ Advanced (Stage II-IV) disease ☐ Metastatic disease ☐ Recurrent disease  
☐ As adjuvant therapy ☐ Metastatic disease  
☐ No response to preoperative systemic therapy  
☐ Other \_\_\_\_\_
4. What is the requested regimen?  
☐ Single agent  
☐ Single agent (concurrent use with a gonadotropin-releasing hormone (GnRH) analog is allowed)  
☐ In combination with abiraterone and prednisone or prednisolone  
☐ The requested medication in combination with bevacizumab (e.g., Avastin)  
☐ Other \_\_\_\_\_
5. Is the patient currently receiving treatment with the requested medication?  
☐ Yes ☐ No *If No, skip to #9*
6. *If the diagnosis is breast cancer*, is the requested medication being used for adjuvant treatment of early-stage, HER2-negative, BRCA-mutated breast cancer with high-risk of recurrence?  
☐ Yes ☐ No ☐ N/A - diagnosis is NOT breast cancer
7. Has the patient experienced disease progression or an unacceptable toxicity while on the current regimen?  
☐ Yes ☐ No
8. How many months has the patient received therapy with the requested medication? \_\_\_\_\_ months

**Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Lynparza SGM - 7/2023a.

**CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081**

**Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • [www.caremark.com](http://www.caremark.com)**

9. Does the patient have deleterious or suspected deleterious germline or somatic BRCA mutation?

**ACTION REQUIRED: If Yes, attach laboratory report confirming BRCA mutation status.**

☐ Yes ☐ No ☐ Unknown ☐ N/A - Patient has prostate cancer

**Complete the following section based on the patient's diagnosis, if applicable.**

Section A: Breast Cancer

10. Will the requested drug be used as adjuvant therapy? ☐ Yes ☐ No

11. Does the patient have human epidermal growth factor receptor 2 (HER2) negative disease?

**ACTION REQUIRED: If yes, attach test results or chart note(s) confirming HER2 negative disease.**

☐ Yes ☐ No ☐ Unknown

12. Has the patient already completed neoadjuvant/adjuvant chemotherapy? ☐ Yes ☐ No

13. In which of the following settings will the requested medication be used?

☐ Hormone receptor-negative breast cancer with any residual disease

☐ Hormone receptor-negative breast cancer with either tumor size of 2cm or greater, or any involved axillary

☐ Hormone receptor-positive breast cancer with 4 or more positive lymph nodes

☐ Hormone receptor-positive breast cancer with any residual disease and a CPS+EG (clinical stage, pathologic stage, estrogen receptor status and tumor grade) score of 3 or greater following preoperative therapy

☐ Other \_\_\_\_\_

Section B: Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Continuation

14. Is the requested medication being used for any of the following?

☐ First-line maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with bevacizumab

☐ First line maintenance treatment of advanced BRCA mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer

☐ None of the above

15. Has the patient experienced a complete response while using the requested drug as first-line maintenance treatment?

☐ Yes ☐ No

16. How long has the patient been treated with the requested drug after achieving a complete response?

\_\_\_\_\_ years \_\_\_\_\_ months

Initiation

17. Is the requested medication being used as maintenance treatment? ☐ Yes ☐ No

18. Is the patient in a complete or partial response to chemotherapy? ☐ Yes ☐ No

19. How many prior lines of platinum-based therapy has the patient completed? \_\_\_\_\_ lines

20. Has the patient received bevacizumab (e.g. Avastin) during primary therapy? ☐ Yes ☐ No

Section C: Pancreatic Adenocarcinoma (Pancreatic Cancer)

21. Will the requested medication be used as maintenance therapy for pancreatic adenocarcinoma? ☐ Yes ☐ No

22. Has the patient received a first-line platinum-based chemotherapy (e.g., cisplatin, carboplatin) for at least 16 weeks?

☐ Yes ☐ No

23. Has the disease progressed during first line platinum based chemotherapy? ☐ Yes ☐ No

Section D: Prostate Cancer

24. Is the disease castration-resistant? ☐ Yes ☐ No

**Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Lynparza SGM - 7/2023a.

**CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081**

**Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • www.caremark.com**

25. Does the patient have a deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutation (e.g., BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, RAD54L)? **ACTION REQUIRED: If Yes, attach test results or chart note(s) confirming HRR mutation status.** ☐ Yes ☐ No ☐ Unknown
26. Has the patient progressed on prior androgen receptor-directed therapy? ☐ Yes ☐ No
27. Does the patient have a deleterious or suspected deleterious BRCA mutation? **ACTION REQUIRED: If Yes, attach test results or chart note(s) confirming BRCA mutation status.** ☐ Yes ☐ No ☐ Unknown
28. Will the patient receive concurrent therapy with a gonadotropin-releasing hormone (GnRH) analog? ☐ Yes ☐ No
29. Has the patient had a bilateral orchiectomy? ☐ Yes ☐ No

Section E: Uterine Leiomyosarcoma

30. Does the patient have BRCA altered uterine leiomyosarcoma? **ACTION REQUIRED: If Yes, attach laboratory report confirming BRCA mutation status.** ☐ Yes ☐ No ☐ Unknown
31. Will the requested medication be used as second-line therapy? ☐ Yes ☐ No

***I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.***

X \_\_\_\_\_  
Prescriber or Authorized Signature

\_\_\_\_\_  
Date (mm/dd/yy)

**Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155**

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Lynparza SGM - 7/2023a.

**CVS Caremark Prior Authorization • 1300 E. Campbell Road • Richardson, TX 75081  
Phone: 1-866-814-5506 • Fax: 1-866-249-6155 • www.caremark.com**